The global injectable drug delivery market size was valued at USD 561.0 billion in 2021 and is projected to reach up to 1,223.0 million in 2030, with a CAGR of 9.0% in the forecasted period.
The rising prevalence of cancer, increasing incidences of chronic diseases are driving the market growth. Moreover, the rise in biologics market is also among the prominent factors for the market growth in the forecasted period.
One of the substantial factors driving the growth of global injectable drug delivery market is rising prevalence of cancer. As per the International Agency for Research on Cancer, 1 in 5 individuals will develop cancer during their lifetime by December 2020, with 1 in 8 men and 1 in 11 women dying from the disease globally. According to the International Agency for Research, cancer cases and deaths will grow up to 19.3 million cases and 10 million deaths in 2020, up from 18 million cases and deaths in 2018. Moreover, the major market players are concentrating on new product development and launches. For instance, the U.S. Food and Drug Administration approved Apretude for pre-exposure prophylaxis to lower the risk of sexually acquired HIV in adults weighing at least 35 kg in December 2021.
The COVID-19 pandemic has both valuable and negative impacts on the healthcare sector. The escalating COVID-19 patient populace is placing strain on healthcare systems. Due to the improved demand for medical things such as injections and pre-filled syringes, manufacturers have enhanced their making capacity to keep up with demand. Additionally, the government around the globe is backing towards the growth of injectable drugs delivery market. The government is profoundly investing for the growth and launch of novel injectable drugs delivery in the market.
Type Insights
The devices segment accounted largest revenue share in 2021. The growing prevalence of chronic disorders is leading to an increase in overall syringe practice, predominantly disposable syringes. The cardiovascular illnesses, diabetes, and obesity have been found to be leading causes of death from chronic disorders. As populace surge is believed to be the critical factor in emerging nations, this is likely to have the highest impact all around the world.
Therapeutic Application Insights
The auto-immune diseases segment hold the largest revenue share in 2021. The immune system bouts and terminates its own body tissue in autoimmune disorders. The diabetes, rheumatoid arthritis, lupus, and other auto-immune diseases are amongst the most frequent diseases. Anti-inflammatory medicines, immune suppressants, and other medicines have been approved to treat auto-immune diseases.
The oncology segment is fastest developing segment of the injectable drugs delivery market in 2021. The rising prevalence of cancer is fuelling the growth of the segment. As per the data of the American Cancer Society, by 2020, there will be around 1,806,590 cancer patients in the U.S. alone, up 31% from 2010.
Distribution Channel Insights
The hospitals segment holds the maximum share in the injectable drugs delivery market in 2021. This is attributed to an increase in the patient’s admitted to hospitals with acute and chronic wounds. Moreover, growth of the segment is also being compelled by the surge in the number of individual clinics in developed and emerging countries.
The retail pharmacy stores segment is predicted to show substantial growth over the forecasted period. The retail pharmacies trade pharmaceutical medications and drugs. These stores provide generic and branded medications, and other pharmaceutical supplies. The increasing preference of patients for purchasing injectable drugs delivery from these stores is boosting the growth of the segment.
Regional Insights
North America is expected to dominate the injectable drugs delivery market in 2021. The rise of injectable drugs delivery market in North America region is being accredited to the rising prevalence of numerous disorders. As per the Alzheimer’s Association, around 6.2 million Americans aged 65 and older will have Alzheimer’s disease by 2020. There are around 3.8 million women and 2.4 million men among those patients. Furthermore, increasing adoption of approaches by market players are also aiding the growth of North America injectable drugs delivery market. For instance, in July 2020, Piramal Critical Care collaborated with Medivant Healthcare, to answer the substantial shortage of injectable medications in hospitals across the nation.
Increased R&D investments, government initiatives to increase awareness about chronic diseases, and rise in healthcare spending are some of the factors that are driving the growth of the injectable drug delivery market in these regions.
Europe, is predicted to grow at the fastest rate during the forecasted period. The UK holds the largest share in the injectable drugs delivery market in Europe region. The Europe injectable drugs delivery market is attributed to the factors such as the rise of the biologics market, increasing incidence of chronic disorders, and the growing demand for self-injection devices are all contributing to this trend. The other factors impelling the growth of injectable drugs delivery market in Europe region are escalating disposable income, growing number of partnerships, and increasing awareness about safety and comfort.
However, a considerably large patient pool in the Asia Pacific region will provide probable growth openings for players in the injectable drug delivery market.
Key Companies Insights
Key players are aiming on their technological partnerships, collaborations, and merger & acquisitions strategies to gain an economical edge and grow their product portfolio & business footmarks. The Covid-19 pandemic hindered the healthcare systems worldwide and driven the market players to transform products for unexploited opportunities.
Some of the key players operating in the global injectable drug delivery market include:
• BD
• Pfizer Inc.
• Teva Pharmaceuticals Industries Ltd.
• Eli Lilly and Company
• Baxter International, Inc.
• Sandoz
• Terumo
• Schott AG
• Gerresheimer
• Ypsomed
• Bespak
• B. Braun Melsungen
• Other players
Segments
By Type
• Devices
o Conventional Injectables
o Pre-Filled Syringes
o Auto-Injectors
o Pen-Injectors
• Formulations
By Formulation Packaging
• Ampules
• Vials
• Cartridges
• Bottles
By Therapeutic Application
• Auto-immune diseases
• Hormonal Disorders
• Orphan Diseases
• Oncology
• Others
By Usage Pattern
• Curative Care
• Immunization
• Other
By Site of Administration
• Skin
• Circulatory/Musculoskeletal
• Organs
• Central Nervous System
By Distribution Channel
• Hospitals & Clinics
• Retail Pharmacy Stores
• Others
By Facility of Use
• Hospitals & Clinics
• Home Care Settings
• Other
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt
Reasons to Get this Report:
The analysis covers global market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global market across sections such as also application and representatives.
In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and global market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of global market; high-growth regions; and market drivers, restraints, and also market chances.
Additionally, the analysis also has a comprehensive review of the crucial players on the global market together side their company profiles, SWOT analysis, latest advancements, and business plans.
